Quantcast

Latest Osteonecrosis of the jaw Stories

2010-10-16 15:45:00

EAST HANOVER, N.J., Oct. 16 /PRNewswire/ -- Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast® (zoledronic acid) injection in postmenopausal women with osteoporosis.(1) The study of more than 1,200 women was presented this weekend at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, ON, Canada. The study showed that Reclast maintained bone mass in...

2010-10-14 16:01:00

THOUSAND OAKS, Calif., Oct. 14 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced that results from several Prolia(TM) (denosumab) studies, as well as analyses of the growing global burden of osteoporosis, will be presented at the 2010 American Society for Bone and Mineral Research (ASBMR) annual meeting in Toronto, Ontario from Oct. 15-19, 2010. "The continued need to reduce fractures caused by postmenopausal osteoporosis is reinforced by data that will be presented at this year's...

2010-10-10 05:56:00

THOUSAND OAKS, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced results from two integrated analyses of head-to-head pivotal Phase 3 trials comparing denosumab to Zometa® (zoledronic acid), the current standard of care in the prevention of skeletal related events (SREs) in patients with advanced malignancies involving bone. In these separate analyses, denosumab demonstrated a clinically meaningful, consistent and robust treatment effect...

2010-09-27 17:34:41

Aging disrupts the balance between bone formation and bone destruction, resulting in osteoporosis, which is characterized by reduced bone mass and increased risk of fracture. Recent data have suggested that this imbalance is a result of a decrease in formation of bone forming osteoblast cells from mesenchymal cells upon aging. Instead, these cells form more fat cells. Insight into this age-related switch in cell type generation has now been provided by a team of researchers, led by Hiroshi...

2010-09-14 18:32:36

Expert panel calls for additional product labeling, international patient registry A widely prescribed class of drugs is highly effective in reducing common bone fractures in people with osteoporosis, but an expert panel announced today that these same drugs "“ when used long term "“ may be related to unusual but serious fractures of the thigh bone. In the most comprehensive scientific report to date on the topic, the task force reviewed 310 cases of "atypical femur fractures,"...

2010-09-03 17:48:50

Research: Oral bisphosphonates and risk of cancer of the esophagus, stomach and colorectum: Case-control analysis within a UK primary care cohort People who take oral bisphosphonates for bone disease over five years may be doubling their risk of developing oesophageal cancer (cancer of the gullet), according to a new study published on bmj.com today. Oral bisphosphonates are a type of drug used to treat osteoporosis and other bone diseases and are the most commonly recommended treatment for...

2010-08-06 14:30:00

NEW YORK, Aug. 6 /PRNewswire/ -- The Bone and Cancer Foundation (BCF) is announcing the publishing of two new patient publications on Pain Management and Physical Therapy and other Rehabilitation Therapies. Other publication topics include: Breast Cancer, Prostate Cancer, Lung Cancer, Osteonecrosis of the Jaw, Vitamin D, Surgery, Myeloma and Osteosarcoma. All publications are available free of charge, both in print and online. www.boneandcancerfoundation.org offers new resources for...

2010-06-05 14:00:00

CHICAGO, June 5 /PRNewswire-USNewswire/ -- Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented preliminary data that shows nitrogen-containing bisphosphonates, therapeutic agents used to promote bone health and inhibit resorption, may cause a slightly poorer survival rate in post-menopausal women with early stage breast cancer who take them for their anti-osteoporosis properties. The findings were announced today at the 2010 American Society of Clinical Oncology...

2010-06-05 07:27:00

EAST HANOVER, N.J., June 5 /PRNewswire/ -- New data to be presented tomorrow at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, show that the addition of Zometa® (zoledronic acid) to first-line chemotherapy significantly improved overall survival for newly diagnosed multiple myeloma patients by 16% (P=0.0118) and progression-free survival by 12% (P=0.0179) compared with oral clodronate plus first-line chemotherapy(1). The 5.5...

2010-06-05 07:09:00

THOUSAND OAKS, Calif., June 5 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial which compared the efficacy and safety of denosumab versus Zometa® (zoledronic acid) in 1,901 patients with hormone-refractory prostate cancer and bone metastases. The study met its primary and secondary endpoints and demonstrated denosumab's superiority over Zometa in delaying or preventing skeletal related events (SREs). These...


Word of the Day
maffling
  • To stammer.
  • Present participle of maffle, to stammer.
  • A simpleton.
The word 'maffle' may come from a Dutch word meaning 'to move the jaws' or a French word meaning 'having large cheeks'.